Aandeel STSA SATSUMA PHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren
Inactief instrument

Andere talen Satsuma Pharmaceuticals, Inc.

Aandelen

STSA

US80405P1075

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from NASDAQ Composite Index
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index
Insider Buy: Satsuma Pharmaceuticals
Satsuma Pharmaceuticals : Termination of Material Agreement - Form 8-K
Satsuma Pharmaceuticals, Inc. Announces CFO Changes
Satsuma Pharmaceuticals, Inc. Announces CEO Changes
Satsuma Pharmaceuticals, Inc. Announces Board Changes
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine Nasal Powder Product for the Acute Treatment of Migraine
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review
SATSUMA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceuticals, Inc. - STSA
SATSUMA PHARMACEUTICALS, INC. : Other Events (form 8-K)
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at the 75th American Academy of Neurology Annual Meeting
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers STSA
  4. Nieuws Satsuma Pharmaceuticals, Inc.
  5. Andere talen